United Therapeutics (NASDAQ:UTHR) CFO James Edgemond Sells 10,000 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $565.63, for a total value of $5,656,300.00. Following the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $10,676,831.88. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

James Edgemond also recently made the following trade(s):

• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $572.94, for a total value of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $564.11, for a total value of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total value of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $573.03, for a total value of $5,730,300.00.
• On Thursday, May 7th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $578.58, for a total value of $5,785,800.00.
• On Monday, May 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $576.93, for a total value of $5,769,300.00.
• On Thursday, April 30th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.61, for a total value of $5,726,100.00.
• On Monday, April 27th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $568.83, for a total value of $5,688,300.00.
• On Wednesday, April 22nd, James Edgemond sold 364 shares of United Therapeutics stock. The stock was sold at an average price of $575.85, for a total value of $209,609.40.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $5.75 during mid-day trading on Friday, reaching $556.34. The company’s stock had a trading volume of 645,038 shares, compared to its average volume of 481,449. The firm has a market capitalization of $23.62 billion, a PE ratio of 20.54, a P/E/G ratio of 1.84 and a beta of 0.60. The stock has a fifty day moving average of $565.98 and a two-hundred day moving average of $515.55. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s revenue was down 1.6% on a year-over-year basis. During the same period last year, the company earned $6.63 EPS. Analysts anticipate that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. Janus Henderson Group PLC raised its position in United Therapeutics by 8.9% during the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Bull Harbor Capital LLC purchased a new stake in United Therapeutics during the first quarter valued at approximately $494,000. Strategic Investment Advisors MI raised its position in United Therapeutics by 20.5% during the first quarter. Strategic Investment Advisors MI now owns 9,752 shares of the biotechnology company’s stock valued at $5,782,000 after purchasing an additional 1,662 shares during the period. Talon Private Wealth LLC purchased a new stake in United Therapeutics during the first quarter valued at approximately $3,038,000. Finally, Royal Bank of Canada raised its position in United Therapeutics by 3.3% during the first quarter. Royal Bank of Canada now owns 59,152 shares of the biotechnology company’s stock valued at $35,075,000 after purchasing an additional 1,864 shares during the period. 94.08% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on UTHR. Royal Bank Of Canada dropped their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Cantor Fitzgerald increased their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, Morgan Stanley set a $516.00 price target on United Therapeutics in a research note on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.